Login to Your Account



Slowed Cognitive Decline May Be Path Forward

Lilly's Solanezumab Miss Is Another Setback in Alzheimer's

By Marie Powers
Staff Writer

Monday, August 27, 2012
Early Friday, Eli Lilly and Co. reported that Phase III Alzheimer's candidate solanezumab missed both the cognitive and functional endpoints in its two double-blind, placebo-controlled EXPEDITION trials in patients with mild-to-moderate disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription